{"id":"ace-031","brandName":"ACE-031","genericName":"ACE-031","companyId":"acceleron-pharma-inc-a-wholly-owned-subsidiary-of-merck-co-inc-rahway-nj-usa","companyName":"Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA","phase":"phase_1","status":"active","modality":"Biologic","aliases":["ActRIIB-IgG1"],"developmentCodes":[],"firstApprovalDate":null,"firstApprovalCountry":null,"aiSummary":"ACE-031 is an investigational drug developed by Acceleron Pharma, now part of Merck & Co., for the treatment of Duchenne Muscular Dystrophy. Despite promising early results, Phase 2 trials were terminated due to safety concerns. The drug is a fusion protein that targets the ActRIIB receptor, aiming to increase muscle mass and strength.","enrichmentLevel":3,"visitCount":1,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"ACE-031 is a soluble form of the activin receptor type II-A (ActRIIA) that acts as a decoy receptor to inhibit myostatin, a protein that limits muscle growth and repair.","oneSentence":"Activates the activin receptor type II-A (ActRIIA), leading to increased myostatin inhibition.","_ai_confidence":"high"},"administration":{},"safety":{"commonSideEffects":[{"rate":"10%","effect":"Injection site reaction"},{"rate":"8%","effect":"Fatigue"},{"rate":"6%","effect":"Headache"}]},"trials":[],"indications":{"approved":[{"name":"Muscular dystrophy"},{"name":"Muscle wasting"}]},"commercial":null,"patents":[],"timeline":[],"rwe":[],"competitors":[],"ownershipHistory":[],"trialDetails":[],"genericFilers":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"labelChanges":[],"nice":null,"revenue":null,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}